Effect of 0.1% Fluorometholone on the Prevention of Eye Disorders Caused by High-Dose Cytarabine Therapy: a Propensity Score Analysis

High-dose cytarabine (HiDAC) is known to cause eye disorders as a side effect of its therapeutic use. As the prophylactic effects of various eye drops have been reported, we retrospectively investigated the prophylactic effects of 0.1% fluorometholone eye drops on eye disorders caused by HiDAC using a propensity score analysis. We targeted patients who were hospitalized and given at least 1 g/m 2 cytarabine (AraC) twice per day between April 2011 and March 2018. We investigated patients who received 0.1% fluorometholone eye drops selected by the physician 4 (FM4) or 6 (FM6) times per day in both eyes from the beginning of HiDAC treatment until 48 h after treatment. Propensity score matching identified 23 patients in each group. The incidence of eye disorders was 13.0% in FM4 patients and 26.1% in FM6 patients. There were no differences in the incidence of eye disorders in terms of either the cumulative dose of AraC or the prophylactic method used. FM4 is considered a convenient treatment to prevent HiDAC-induced eye disorders with no adverse effects on the patient’s quality of life.